Baird Keeps Outperform on Abbott and Danaher, Raises Price Targets
Baird lifted its Abbott Labs target to $123 from $121 and Danaher's to $254 from $246, keeping Outperform ratings, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires, citing Benzinga data, reported that Baird kept its Outperform rating on Abbott Labs and raised its price target from $121 to $123 per share.
A similar entry followed for Danaher: Baird also held Outperform there and increased its target from $246 to $254.
why it matters
Price target changes from a single broker rarely move the broader market, but they show how analysts view the outlook for two large healthcare technology and diagnostics companies. Healthcare investors often weigh such updates alongside earnings and macro data.
tags
instruments
sources
- Abbott Labs Is Maintained at Outperform by Baird — Dow Jones Newswires, 22 October 2026 at 11:31 UTC
- Danaher Is Maintained at Outperform by Baird — Dow Jones Newswires, 22 October 2026 at 11:33 UTC
- Abbott Labs Is Maintained at Outperform by RBC Capital — Dow Jones Newswires, 22 October 2026 at 15:48 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗